Literature DB >> 19616317

GABAergic analgesia: new insights from mutant mice and subtype-selective agonists.

Hanns Ulrich Zeilhofer1, Hanns Möhler, Alessandra Di Lio.   

Abstract

Gamma-aminobutyric acid (GABA) is the most abundant inhibitory neurotransmitter in the brain where it regulates many physiological functions including sleep, anxiety, reward and memory formation. GABAergic neurons and ionotropic GABA(A) receptors are also found in the spinal cord dorsal horn where they control the propagation of pain signals from the periphery to higher central nervous system areas. Recent evidence indicates that diminished inhibitory control at this site is a major factor in chronic pain syndromes. So far, this knowledge could not be translated into clinical pain therapy, probably because of the widespread actions of GABA in the central nervous system. The identification of GABA(A) receptor subtypes responsible for spinal antihyperalgesic effects has recently opened new avenues for the development of subtype-selective modulators of GABA(A) receptors. First results raise hopes that such compounds will be active against inflammatory and neuropathic pain but devoid of many of the side-effects of the established benzodiazepine-like drugs.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19616317     DOI: 10.1016/j.tips.2009.05.007

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


  29 in total

1.  Nonnociceptive afferent activity depresses nocifensive behavior and nociceptive synapses via an endocannabinoid-dependent mechanism.

Authors:  Sharleen Yuan; Brian D Burrell
Journal:  J Neurophysiol       Date:  2013-09-11       Impact factor: 2.714

2.  Regulation of GABA(A) receptor dynamics by interaction with purinergic P2X(2) receptors.

Authors:  Amulya Nidhi Shrivastava; Antoine Triller; Werner Sieghart; Isabella Sarto-Jackson
Journal:  J Biol Chem       Date:  2011-02-22       Impact factor: 5.157

3.  Antinociceptive effect of flavonol and a few structurally related dimethoxy flavonols in mice.

Authors:  Vijaykumar Sayeli; Jagan Nadipelly; Parimala Kadhirvelu; Binoy Varghese Cheriyan; Jaikumar Shanmugasundaram; Viswanathan Subramanian
Journal:  Inflammopharmacology       Date:  2019-03-08       Impact factor: 4.473

Review 4.  GABA pharmacology: the search for analgesics.

Authors:  Kenneth E McCarson; S J Enna
Journal:  Neurochem Res       Date:  2014-02-15       Impact factor: 3.996

5.  Inhibition of carbonic anhydrase augments GABAA receptor-mediated analgesia via a spinal mechanism of action.

Authors:  Marina N Asiedu; Galo L Mejia; Christian A Hübner; Kai Kaila; Theodore J Price
Journal:  J Pain       Date:  2014-01-09       Impact factor: 5.820

6.  Concomitant facilitation of GABAA receptors and KV7 channels by the non-opioid analgesic flupirtine.

Authors:  Felicia Klinger; Petra Geier; Mario M Dorostkar; Giri K Chandaka; Arsalan Yousuf; Isabella Salzer; Helmut Kubista; Stefan Boehm
Journal:  Br J Pharmacol       Date:  2012-07       Impact factor: 8.739

Review 7.  Fibromyalgia and sleep in animal models: a current overview and future directions.

Authors:  Cristina Frange; Camila Hirotsu; Helena Hachul; Paula Araujo; Sergio Tufik; Monica L Andersen
Journal:  Curr Pain Headache Rep       Date:  2014

Review 8.  Beyond classical benzodiazepines: novel therapeutic potential of GABAA receptor subtypes.

Authors:  Uwe Rudolph; Frédéric Knoflach
Journal:  Nat Rev Drug Discov       Date:  2011-07-29       Impact factor: 84.694

9.  Different SNP combinations in the GCH1 gene and use of labor analgesia.

Authors:  Fatimah Dabo; Alfhild Grönbladh; Fred Nyberg; Inger Sundström-Poromaa; Helena Akerud
Journal:  Mol Pain       Date:  2010-07-15       Impact factor: 3.395

10.  GABA increases electrical excitability in a subset of human unmyelinated peripheral axons.

Authors:  Richard W Carr; Ruth Sittl; Johannes Fleckenstein; Peter Grafe
Journal:  PLoS One       Date:  2010-01-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.